U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, announced on Tuesday he will not seek another term in Congress.
“Even the best of stories has a last chapter,”
…
Articles by : Tom Mirga, Editor at Large
The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential
…
The Illinois legislature has voted to forbid pharmacy benefit managers, third party payers, and Medicaid managed care organizations from discriminating against 340B covered entities and their contract pharmacies.
At least three other states have passed similar legislation so far in
…
Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity
…
Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.
J&J has not responded
…
Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.
The Centers for Medicare & Medicaid Services (CMS) Office of the Actuary
…
The next period for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, April 1, and end on Friday, April 15.
Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during
…
Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.
The state hospital association said
…News Alert
HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
HRSA told BI in a March 29
…